Monotherapy in adults and elderly persons
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Treatment of epilepsy with a single drug has many advantages. Potential benefits of monotherapy vs polytherapy include fewer adverse events and better tolerability, avoidance of drug-drug interactions, reduced treatment costs, and improved compliance. Initial treatment should always be monotherapy. Avoidance of pharmacokinetic interactions is a major advantage. Some patients who have achieved seizure control with polytherapy may be candidates for conversion to monotherapy because there is no conclusive evidence that polytherapy provides better seizure control in the majority of patients. Recently published treatment guidelines that take into account the efficacy and tolerability profiles of new and old antiepileptic drugs (AEDs) provide recommendations for drug selection in adults. Elderly patients with epilepsy face unique treatment challenges, which include age-related reductions in liver or kidney function that may alter drug pharmacokinetics. Older persons are more sensitive to CNS side effects; some drugs may exacerbate preexisting problems such as tremor, ataxia, and cognitive difficulty. Many common conditions in the elderly are treated with drugs that are subject to interactions with AEDs. Complex dosing schedules and high drug costs are often barriers to proper care. For all these reasons, monotherapy is especially attractive for the elderly.
Footnotes
-
This supplement was supported by an educational grant from Novartis Pharmaceuticals Corporation.
Disclosure: Dr. Faught has receired honoraria in excess of $10.000 from the sponsor during the course of this study.
Neurology® supplements are not peer-reviewed. Information contained in Neurology® supplements represents the opinions of the authors. These opinions are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology®.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- RATIONALE FOR MONOTHERAPY
- PHARMACOKINETIC INTERACTIONS BETWEEN ANTIEPTILEPTIC DRUGS
- CANDIDATES FOR MONOTHERAPY
- CHOICE OF DRUG FOR MONOTHERAPY: TREATMENT GUIDELINES
- CHOICE OF DRUG FOR MONOTHERAPY: SIDE EFFECTS
- CHALLENGES IN TREATING EPILEPSY IN ELDERLY ADULTS
- REASONS FOR POLYTHERAPY
- SUMMARY
- Footnotes
- REFERENCES
- Figures & Data
- Info & Disclosures
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Contemporary Issues in Neurologic Practice
Trends in antiepileptic drug prescribing for older patients with new-onset epilepsy: 2000–2004M.J.V. Pugh, A. C. Van Cott, J. A. Cramer et al.Neurology, May 27, 2008 -
Articles
Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behaviorFrank Andersohn, René Schade, Stefan N. Willich et al.Neurology, July 26, 2010 -
Articles
Health care costs decline after successful epilepsy surgeryJ. T. Langfitt, R. G. Holloway, M. P. McDermott et al.Neurology, April 16, 2007 -
Consensus Conference on Current Clinical Practice: Articles
Medical management of epilepsy in adultsRichard H. Mattson et al.Neurology, November 01, 1998